AKESO's stock price dropped 5.42% during the intraday session following the release of its full-year 2025 financial results, which showed a widening annual loss despite strong revenue growth.

The biopharmaceutical company reported that its revenue increased by 43.9% to CNY 3.1 billion for FY2025, driven by commercial momentum from its immuno-oncology products cadonilimab and ivonescimab after their first inclusion in China's national reimbursement drug list. However, the company's loss attributable widened significantly to CNY 1.11 billion, which appears to have disappointed investors and triggered the sell-off.

While Akeso highlighted progress in its pipeline strategy centered on bispecific antibodies and expansion into additional therapeutic areas, and noted that overseas development for ivonescimab advanced through partner Summit Therapeutics with a BLA submission accepted by the FDA, the substantial widening of losses overshadowed these positive developments in today's trading.